News Summary: Pfizer painkiller patent extended

News Summary: Pfizer's painkiller Celebrex gets longer patent; company sues generic drugmakers

Associated Press

PATENT WIN: Drugmaker Pfizer gets an 18-month extension on a key patent for its blockbuster anti-inflammatory painkiller, as the federal government grants a new patent for Celebrex. It replaces a patent invalidated by a federal appeals court due to technical deficiencies.

THE IMPACT: The new patent for Celebrex, Pfizer's fifth-best-selling drug, runs till December 2015. The additional time could bring Pfizer a few billion in extra revenue.

BACKSTOPPPING: Pfizer also is suing five generic drugmakers who had hoped to start selling generic Celebrex in May 2014, to prevent any generic sales by them until December 2015.

View Comments (0)